AIIMS Patna Resident doctors accuse MLA of assault, go on strike

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Resident doctors at the All India Institute of Medical Sciences (AIIMS) Patna went on a strike on Friday against the alleged manhandling of hospital staff by Sheohar MLA Chetan Anand. The incident reportedly escalated into a scuffle after the MLA’s supporters allegedly attempted to enter the hospital premises. When security personnel attempted to stop them, a heated exchange broke out between the two sides.

Healthcare services were affected at AIIMS Patna on Friday as resident doctors boycotted work in protest against the alleged high-handedness of Sheohar MLA Chetan Anand.

In a letter to the medical superintendent of AIIMS Patna, the Resident Doctors’ Association (RDA) sought legal action against Anand and the deployment of security personnel on the hospital premises.

“The MLA, his wife and his armed guards forcibly entered the hospital area, physically assaulted security staff, threatened resident doctors with death and brandished a firearm within hospital premises. A hospital guard was brutally injured and resident doctors were subjected to threats and abuse inside their own workplace,” the RDA alleged in the letter, according to a PTI news report.

For more information, click on the link below:

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Powered by WPeMatico

No report on Bias or transparency issues in NMC: Health Minister Tells Parliament

New Delhi: Responding to the concerns raised on the alleged lack of transparency in the National Medical Commission (NMC) and the possible bias in favour of the doctors at the expense of the patients, the Minister of State for Health, Smt. Anupriya Patel refuted such claims and stated that “No such report has been received in the Ministry of Health and Family Welfare.”

Further, the MoS Health informed the Parliament that the Ethics Board of NMC regulates the professional conduct and promotes medical ethics amongst doctors and the mechanism to handle complaint (s) with regard to professional misconduct by doctors are provided under Clause 8.2 of the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002.

The Minister was responding to questions raised by Dr. M. Thambidurai, who sought to know if the Government was aware of the reports stating that NMC lacks transparency and is biased in favour of doctors at the expense of patients. He also sought to know the steps taken by the Government to ensure that NMC functions transparently and fairly.

Also Read: Patients can file appeals against state medical councils orders: NMC

In response, MoS Health Smt Patel informed, “No such report has been received in the Ministry of Health and Family Welfare. Further, the Ethics and Medical Registration Board (EMRB) of National Medical Commission (NMC) regulates the professional conduct and promotes medical ethics amongst the medical professionals. Further, Clause 8.2 of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 provides for a mechanism to handle complaint(s) with regard to professional misconduct by the medical professional (s).”

“To ensure that the NMC functions in a transparent and fair manner, the Central Government appoints amongst others the Chairperson, Presidents of four Autonomous Boards as per the NMC Act, 2019 and Rules made their under. Also, as per Section 4 of the said Act, there are ten ex-officio Members in the Commission which also include heads of medical institutions of national repute. NMC also has twenty-two part-time members drawn from States and elected members of the State Medical Councils,” Minister Patel further added.

As per Clause 8.2 of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, “any complaint with regard to professional misconduct can be brought before the appropriate Medical Council for Disciplinary action. Upon receipt of any complaint of professional misconduct, the appropriate Medical Council would hold an enquiry and give opportunity to the registered medical practitioner to be heard in person or by pleader. If the medical practitioner is found to be guilty of committing professional misconduct, the appropriate Medical Council may award such punishment as deemed necessary or may direct the removal altogether or for a specified period, from the register of the name of the delinquent registered practitioner. Deletion from the Register shall be widely publicized in local press as well as in the publications of different Medical Associations/ Societies/Bodies.”

Previously, under Section 8.8 of the MCI Ethics Regulations 2002, any person (doctors or non medical professionals) could challenge the decision of the State Medical Council before the Apex Medical Commission.

However, after NMC replaced the erstwhile Medical Council of India (MCI), it has reportedly been rejecting patients’ appeals stating that only medical practitioners could file an appeal before the NMC under the NMC Act 2019.

Section 30(3) of the NMC Act 2019 which states, “(3) A medical practitioner or professional who is aggrieved by any action taken by a State Medical Council under sub-section (2) may prefer an appeal to the Ethics and Medical Registration Board against such action, and the decision, if any, of the Ethics and Medical Registration Board thereupon shall be binding on the State Medical Council, unless a second appeal is preferred under sub-section (4).”

Also Read: Patient’s appeal allowed or not? Confusion persists over NMC rejection

Powered by WPeMatico

Additional Professor Post At AIIMS Jodhpur, Applications Open! Here’s HOW To APPLY

Jodhpur: The All India Institute of Medical Sciences (AIIMS Jodhpur) has invited online applications for the Retired Faculty post on a Contract Basis.

AIIMS Jodhpur is one of the 6 new AIIMS established by the Ministry of Health & Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY) to correct regional imbalances in quality tertiary level healthcare in the country and attain self-sufficiency in graduate and postgraduate medical education.

AIIMS Jodhpur Vacancy Details:

Total No of Vacancies: 01

The Vacancies are in the Department of Community Medicine and Family Medicine.

The Last date of submission for online application is 4th AUGUST 2025.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=aiims+jodhpur&location=&job_sector=all

Instructions for eligible candidates:-

The aspiring applicants satisfying the eligibility criteria in all respect can submit their application only through ON-LINE mode. The On-line registration of the application is made available on AIIMS, Jodhpur official website i.e. http://www.aiimsjodhpur.edu.in. Last Date for submission of online application is 04th, August, 2025 (till 05:00 PM). No Documents including online application form is required to be sent, however, all the applicants are advised to keep a copy of online application form with them, along with proof of payment (a Copy of challan /online payment receipt) for their record.

AIIMS, Jodhpur decision final:-

The decision of the AIIMS, Jodhpur in all matters relating to eligibility, acceptance or rejection of the applications, penalty for false information, mode of selection, conduct of examination(s), allotment of examination centers, selection and allotment of posts/organizations to selected candidates will be final and binding on the candidates and no enquiry / correspondence will be entertained in this regard.

Information for Candidates:-

(i) The All-India Institute of Medical Science is an autonomous body established under Act of parliament.

(ii) Service under the Institute is governed by that Act and the Rules & Regulations framed there under.

(iii) Tenure: The appointment is purely on contract basis initially for a period of 01 Years. This appointment will not vest any right to claim by the candidate for regular appointment or permanent absorption in the institute

OR for continued contractual appointment which may be renewed or terminated as decided by the Institute.

(iv) The applicants, who do not have requisite qualifications up to the last date for submission of applications, will not be considered.

(v) Incomplete application(s) will not be considered.

(vi) Closing Date 04th, August, 2025 (upto 5.00 PM).

(vii) The post(s) is/are whole time and private practice of any kind is prohibited.

(viii) The Candidate are likely to be posted at rural health and urban center attached with the institute for the period to be decided by the Institute as applicable.

(ix) AIIMS reserves the rights to increase or decrease the number of vacancies.

(x) Canvassing of any kind will be a disqualification.

(xi) The candidate should not have been convicted by any Court of Law.

(xii) In case any information given or declaration by the candidate is found to be false or if the candidate has willfully suppressed any material information relevant to this appointment, he/she will be liable to be removed from the service and any action taken as deemed fit by the appointing authority.

(xiii) The Competent Authority reserves the right of any amendment, cancellation a n d changes to this advertisement as a whole or in part without assigning any reason or giving notice.

(xiv) The decision of the competent authority regarding interview, verification of documents and selection would be final and binding on all candidates. No representation correspondence will be entertained in this regard.

(xv) All disputes will be subject to jurisdiction of Court of Law at JODHPUR.

Also Read:AIIMS PATNA JOBS 2025: Apply For JR Post Vacancies, Check Last Date Here

Powered by WPeMatico

Health Bulletin 02/August/ 2025

Here is the top health news for today: 

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

The District Consumer Disputes Redressal Commission, Thanjavur, recently directed a Tambaram-based private hospital and its six doctors (including an orthopaedic surgeon, a surgeon, 3 Anaesthetists, and a plastic surgeon) to pay Rs 76 lakh compensation to a patient, who became disabled after undergoing treatment at the hospital.

After undergoing six surgeries at the hospital, the complainant/patient was diagnosed with a compartment syndrome and foot drop. The complainant became 50% disabled, requiring the assistance of a round-the-clock attendant.

The history of the case goes back to 2022, when, after meeting with a two-wheeler accident, the complainant was diagnosed with a fracture in his right knee. On the same day i.e. 15.09.2022, the complainant was admitted to Kasthuri Hospital, Thambaram. The doctors diagnosed a normal ECG, a normal Doppler study of the right lower limb arteries, no evidence of stenosis in the arteries, and right lower limb no deep vein thrombosis. After assessing the complainant, the treating doctor- an orthopaedic surgeon, found no signs of compartment syndrome.

For more information, click on the link below:

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

NMC approves conditional renewal to 22 GMCs in Karnataka

In a major relief for the undergraduate medical education in Karnataka, the National Medical Commission (NMC) has granted conditional renewal and recognition to 22 government medical colleges in Karnataka, which had earlier received show-cause notices from the Commission for deficiencies in infrastructure and faculty requirements.

While granting conditional renewal and recognition to these medical colleges for the academic year 2025-2026, the Apex Medical Commission gave them four months to comply with the NMC standards.

Even though the Commission has not imposed any penalties on any of these 22 GMCs this year, they have been issued warning that admissions will be restricted for the next academic year if the system is not rectified.

Medical Dialogues had previously reported that earlier this year, NMC had issued show-cause notices to 22 government medical colleges in Karnataka for failure to meet standard parameters, including infrastructure and faculty recruitment.

For more information, click on the link below:

NMC grants conditional renewal to 22 GMCs in Karnataka

Delays Hit PGI’s Sarangpur Satellite Centre

A long-awaited healthcare expansion project in Chandigarh, aimed at reducing the heavy patient load on the Post Graduate Institute of Medical Education and Research (PGIMER), continues to face major delays despite multiple approvals and the official transfer of land nearly four years ago.

The Sarangpur satellite centre project, originally proposed in 2017, involves the development of a sprawling 50.76-acre campus intended to house a new MBBS college, advanced treatment centres, and speciality hospitals. The Union Cabinet approved the transfer of the land to PGI in 2019, but the Chandigarh administration only officially handed over possession in November 2021 after prolonged discussions.

Medical Dialogues had previously reported that in a major setback, the Postgraduate Institute of Medical Education and Research, Chandigarh (PGI Chandigarh) has failed to complete the project of the 300-bed hospital at Sangrur within the stipulated timeframe. With the deadline being missed, PGIMER has now set December 2019 as the new deadline for the completion of the hospital at its satellite centre.

For more information, click on the link below:

PGI’s Sarangpur Satellite Centre faces delays despite land transfer

AIIMS Patna Resident doctors accuse MLA of assault, go on strike

Resident doctors at the All India Institute of Medical Sciences (AIIMS) Patna went on a strike on Friday against the alleged manhandling of hospital staff by Sheohar MLA Chetan Anand. The incident reportedly escalated into a scuffle after the MLA’s supporters allegedly attempted to enter the hospital premises. When security personnel attempted to stop them, a heated exchange broke out between the two sides.

Healthcare services were affected at AIIMS Patna on Friday as resident doctors boycotted work in protest against the alleged high-handedness of Sheohar MLA Chetan Anand.

In a letter to the medical superintendent of AIIMS Patna, the Resident Doctors’ Association (RDA) sought legal action against Anand and the deployment of security personnel on the hospital premises.

“The MLA, his wife and his armed guards forcibly entered the hospital area, physically assaulted security staff, threatened resident doctors with death and brandished a firearm within hospital premises. A hospital guard was brutally injured and resident doctors were subjected to threats and abuse inside their own workplace,” the RDA alleged in the letter, according to a PTI news report.

For more information, click on the link below:

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Powered by WPeMatico

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

New Delhi: Biodeal Pharmaceuticals Limited has been directed by the National Pharmaceutical Pricing Authority (NPPA) to submit documents supporting its claim regarding a novel drug delivery system before a final decision can be made on its application for exemption under Para 32(iii) of the Drug Price Control Order (DPCO), 2013, for Midazolam Nasal Spray 1.25% w/v.

The recommendation came during the 69th Multidisciplinary Committee of Experts meeting held on July 3, 2025, where the NPPA reviewed the firm’s exemption request and noted that “the Committee directed that the applicant to provide the documents in support of their claim w.r.t. new delivery system.”

The company applied for price control exemption claiming the formulation was “developed in-house through indigenous research and development involving new drug delivery system.”

However, the committee noted that “Midazolam Nasal Spray 1.25mg/actuation is a scheduled formulation under NLEM 2022 mentioned at Sections 1.3.3 & 5.1.7 of Schedule I of DPCO, 2013.” The current ceiling price effective from April 1, 2025, is Rs. 220.59 per ml, notified via S.O. 1489(E) dated 27.03.2025.

This application was a follow-up to NPPA’s earlier direction in the 68th meeting on June 3, 2025, wherein the firm was asked to present a product demonstration. Complying with the direction, the representative of Biodeal demonstrated the product and submitted the following key points:

“The product has been approved by DCGI as new drug for new indication i.e. Seizure clusters, acute repetitive seizure.”

“The approved pack is for 1.2ml pack size and each actuation contains 1.25mg of the drug. The pack contains 12 actuations, out of which initial 4 sprays needs to be primed in the air, 4 sprays remain in the bottle undelivered. The artwork of the cartoon also claimed delivery of 4 actuation.”

“Applicant submitted that there is no comparator product in the market having same label claim i.e., 4 metered doses.”

“The company has also stated that Midazolam spray 1.25% w/v was never approved by DCG(I) earlier for sales and distribution in the country of India and Midazolam nasal spray is not available in the market.”

The committee, however, disputed this claim, stating:

“Midazolam spray 1.25% w/v is an essential drug under NLEM 2022 and hence has been approved by DCGI. Therefore, the contention that Midazolam spray 1.25% w/v was never approved by DCG(I) earlier for sales and distribution seems incorrect.”

While the company submitted documentation to support its R&D claims, including a DSIR-accredited indigenous research facility, the panel expressed concern about whether the product truly qualifies as a “new delivery system” under Para 32(iii) of DPCO:

“The Committee inquired as how the applicant’s product is a new delivery system as other sprays are also there in the market for this formulation.”

Accordingly, the committee concluded that a decision could not yet be taken and directed the applicant to provide further supporting evidence:

“The Committee directed that the applicant to provide the documents in support of their claim w.r.t. new delivery system.”

Powered by WPeMatico

CDSCO Panel Accepts Phase I Trial Data for Intas’ Denosumab Biosimilar

New Delhi: The Subject Expert Committee (SEC) under the Analgesic and Rheumatology division of the Central Drugs Standard Control Organisation (CDSCO) has reviewed and accepted the final Clinical Study Report (CSR) submitted by Intas Pharmaceuticals Ltd. for its proposed biosimilar Denosumab 120 mg/1.7 ml injection, without raising any objections.

The development was discussed during the SEC meeting held on June 24, 2025, under file number E-54043. The CSR presented data from a Phase I, randomized, double-blind, three-arm, balanced, single-dose, parallel-group clinical trial, conducted under Protocol No. 0568-19. The study aimed to establish pharmacokinetic (PK) and pharmacodynamic (PD) comparability between Intas’ biosimilar Denosumab and the reference biologics Xgeva® from Amgen Inc., USA, and Amgen Europe B.V., The Netherlands.

The trial enrolled healthy adult male volunteers and evaluated bioequivalence and safety of the biosimilar candidate in a controlled setting, an essential step in the development of monoclonal antibody-based biosimilars.

Denosumab is a fully human monoclonal antibody targeting RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), an essential regulator of osteoclasts, which are responsible for bone resorption. The reference product, Xgeva®, is widely approved for preventing skeletal-related events (SREs) in patients with bone metastases from solid tumors, as well as giant cell tumor of bone and hypercalcemia of malignancy.

Intas Pharmaceuticals Ltd., based in Ahmedabad, Gujarat, is a vertically integrated pharmaceutical company known for its strong biologics and biosimilars pipeline. The company has a wide global presence across North America, Europe, and Asia, and is committed to providing high-quality, affordable therapies in critical areas like oncology, rheumatology, and nephrology.

Powered by WPeMatico

Medical Bulletin 02/August/2025

Here are the top medical news for the day:

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds

A new study published in Applied Physiology, Nutrition, and Metabolism has found that insulin levels in saliva can be used as a non-invasive method to detect early signs of metabolic health issues, including Type 2 diabetes, obesity, and heart disease.

Hyperinsulinemia, or elevated insulin levels in the blood, is a well-established marker of poor metabolic health and a predictor of chronic diseases. While blood testing has been the standard, researchers now say that saliva testing could serve as a practical and less invasive alternative.

The study involved 94 healthy participants with a range of body sizes. After fasting, each participant consumed a standardized meal-replacement shake, provided saliva samples at multiple time points, and completed a finger-prick blood glucose test. Researchers found that individuals living with obesity had significantly higher saliva insulin levels compared to leaner participants, even though their blood glucose levels remained similar.

Dr. Hossein Rafiei, co-author of the study, highlighted another compelling finding: some lean participants also showed large spikes in saliva insulin after the meal. “The finding that some people who are lean have high insulin is intriguing. This indicates that saliva insulin may be more useful than measuring someone’s weight or waist size.”

The study also found that waist circumference had the strongest correlation with elevated saliva insulin, more so than BMI, age, or sex. “Our results also suggest that saliva insulin may be better than blood glucose at distinguishing between those who are more metabolically healthy and those who are more likely to live with hyperinsulinemia,” adds Dr. Rafiei.

Researchers hope this method could eventually lead to accessible screening tools that enable early interventions—well before chronic conditions take hold.

Reference: Hossein Rafiei and Jonathan Peter Little. 2025. Saliva insulin concentration following ingestion of a standardized mixed meal tolerance test: influence of obesity status. Applied Physiology, Nutrition, and Metabolism. 50: 1-8. https://doi.org/10.1139/apnm-2024-0532

Study Reveals Artificial Sweetener May Weaken Cancer Immunotherapy

A new study published in Cancer Discovery, a journal of the American Association for Cancer Research, has found that high consumption of sucralose—a common artificial sweetener—may impair the effectiveness of immunotherapy in cancer patients. Researchers reported that patients with melanoma or non-small cell lung cancer who consumed high levels of sucralose had worse outcomes and reduced survival compared to those with lower intake.

Sucralose is widely used as a sugar substitute in diet sodas, coffee, and other low-calorie foods. While often chosen for its ability to help manage blood sugar and weight, this new research suggests it may have unintended consequences for cancer patients undergoing immune checkpoint inhibitor therapies such as anti-PD1 treatment.

To explore this link, researchers used mouse models of adenocarcinoma and melanoma. They found that sucralose disrupted the gut microbiome, increasing bacteria that degrade arginine—an amino acid critical for T cell function. This reduction in arginine led to less effective immune responses and poorer tumor control. “When arginine levels were depleted due to sucralose-driven shifts in the microbiome, T cells couldn’t function properly,” explained lead author Dr. Abby Overacre. “As a result, immunotherapy wasn’t as effective in mice that were fed sucralose.”

However, the researchers also discovered a promising workaround. Supplementing sucralose-fed mice with either arginine or citrulline—a compound that the body converts into arginine—restored the effectiveness of immunotherapy. “That’s why it’s so exciting that arginine supplementation could be a simple approach to counteract the negative effects of sucralose on immunotherapy,” Overacre added.

To test the relevance in humans, the team analyzed dietary data from 132 cancer patients undergoing anti-PD1 therapy. Those with higher reported intake of sucralose-containing foods and drinks had consistently poorer responses across various cancer types and treatment combinations.

A clinical trial is being planned to test citrulline supplementation in patients receiving immunotherapy.

Reference: Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi. Dahmani, Ansen BP. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, Hong Wang, Steven J. Mullett, Kaitlin Bossong, Stacy L. Gelhaus, Dhivyaa Rajasundaram, Lawrence P. Kane, Greg M. Delgoffe, Jishnu Das, Diwakar Davar, Abigail E. Overacre-Delgoffe; Sucralose consumption ablates cancer immunotherapy response through microbiome disruption.. Cancer Discov 2025; https://doi.org/10.1158/2159-8290.CD-25-0247

New Tool Can Calculate Heart Age and Reveal Hidden Cardiovascular Risks: JAMA

Your heart could be aging faster than the rest of your body, according to new research published in JAMA Cardiology. The study, conducted by researchers at Northwestern University Feinberg School of Medicine, found that many U.S. adults have a “heart age” several years older than their actual age. The age gap, the researchers noted, is even more pronounced in men than in women.

To make these findings more accessible and actionable, the research team developed a free online tool called the PREVENT Risk Age Calculator. This tool estimates a person’s heart age based on key health information such as cholesterol levels, blood pressure, BMI, medications, smoking habits, and diabetes status. Instead of presenting risk as a percentage, the calculator expresses it as an age, making it easier to understand.

“Heart age, or PREVENT age, may be particularly useful for patients and clinicians and be more effective in preventing heart disease,” said senior author Dr. Sadiya Khan, the Magerstadt Professor of Cardiovascular Epidemiology at Northwestern. “It translates complex information about the risk of heart attack, stroke or heart failure over the next 10 years into a number that is easier to understand and compare with one we are all familiar with – your actual age.”

To validate the tool, researchers analyzed health data from over 14,000 adults aged 30 to 79 who had no prior history of cardiovascular disease. They calculated heart ages and compared them to the participants’ real ages. The findings showed that the average heart age among women was 55.4—nearly four years older than their chronological age of 51.3. Men, on the other hand, had an average heart age of 56.7, seven years higher than their chronological age of 49.7.

While Dr. Khan noted that a one- or two-year gap may not be significant, a difference of five years or more could be cause for concern. “We hope this new heart age calculator will help support discussions about prevention and ultimately improve health for all people,” he said.

Researchers acknowledged that the definition of “optimal risk” could affect results and that wider testing is needed to determine how easily the tool is understood and adopted in clinical settings.

Reference: Krishnan V, Huang X, Perak AM, et al. PREVENT Risk Age Equations and Population Distribution in US Adults. JAMA Cardiol. Published online July 30, 2025. doi:10.1001/jamacardio.2025.2427

Powered by WPeMatico

Family alleges negligence after newborn dies at Nahan Govt Hospital

Nahan: A newborn baby passed away at Dr. YS Parmar Government Medical College and Hospital in Nahan, with the family accusing doctors of alleged medical negligence.

The incident has sparked outrage after a video surfaced on social media showing the infant’s maternal aunt detailing the alleged lapse.

In the video, the infant’s maternal aunt mentioned that her pregnant sister was admitted to the hospital on July 24. She claims that attending doctors administered doses of labour-inducing medication at 2 am, 6 am, and 10 am. However, despite experiencing intense labour pains for over ten hours, the pregnant woman’s cervical dilation reportedly did not progress beyond two centimetres.

Also Read: Probe ordered after gauze found inside woman’s abdomen after c-section

Despite the evident lack of progress and increasing risk, she alleged, the doctors did not consider a caesarean section or other urgent intervention. By the time medical staff took further action, the baby had already died in the womb.

Further allegations include the absence of on-duty doctors during critical nighttime hours, as well as a lack of essential medical equipment. She stated that the hospital did not have a working foetal heartbeat monitor or a 3D ultrasound machine — both considered vital in managing high-risk deliveries.

She added that the negligence not only resulted in the newborn’s death but also caused immense physical and emotional trauma to her sister. Speaking to Tribune India, Dr Sangeeta Dhillon, Senior Medical Superintendent at the medical college, said no formal complaint had been received in writing as of now. “If a complaint is submitted, action will be taken as per protocol,” she added.

Also Read: Stillbirth due to treatment delay- TN Govt to pay Rs 5 lakh compensation

Medical Dialogues had previously reported that the State Human Rights Commission (SHRC) has directed the Tamil Nadu Government to pay Rs 5 lakh compensation to a woman who delivered a stillborn baby due to allegedly delayed medical treatment at Murukkeri Primary Health Centre (PHC) in Villupuram.

Powered by WPeMatico

Cancer immunotherapy linked to rare liver complication, study warns

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls. Analyzing 634 patient reports from global drug-safety databases (FAERS and VigiBase), scientists found immunotherapy patients had a significantly higher risk of cholestasis than chemotherapy recipients. Those under 65 faced greater danger, and women developed symptoms weeks earlier than men (Median 1.17 vs. 1.90 months).

Anti-PD-1 drugs (e.g., pembrolizumab) and combination therapies posed the highest risk. In mice, combined anti-CTLA-4/anti-PD-L1 drugs caused severe bile duct injury. Molecular analysis linked the condition to disrupted bile acid metabolism and inflammation pathways.

“This isn’t about abandoning immunotherapies-they save lives,” stresses senior author Peng Luo, PhD, of Southern Medical University. “But we must monitor liver function aggressively, especially in the first month for women and young adults. Catching cholestasis early prevents irreversible damage.”

Surprisingly, cholestasis often occurred without classic hepatitis symptoms, suggesting routine liver tests alone may miss it. The team urges adding bile acid level checks to standard monitoring.

Reference:

Yan, Xinronga,†; Li, Zhengruib,†; Jiang, Aiminc,†; Chen, Jinghonga,†; Huang, Xufengd,e; Hajdu, Andrásd; Wong, Hank Z.H.f; Cheng, Quang,h,*; Zhang, Jiani,*; Lin, Anqia,*; Luo, Penga,*. Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and vigiBase. International Journal of Surgery ():10.1097/JS9.0000000000002607, June 05, 2025. | DOI: 10.1097/JS9.0000000000002607.

Powered by WPeMatico

Study finds living in rural environments in first 5 years of life could be a risk factor for developing type 1 diabetes

New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) suggests that living in a rural environment in the first five years of life could increase the risk of developing type 1 diabetes compared with living in urban environments.

Powered by WPeMatico